Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental performance in Q1.

Here's Why You Should Add Hologic Stock in Your Portfolio

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Hologic (HOLX) Down 12.1% Since Last Earnings Report: Can It Rebound?

Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.

Hologic Expands Panther Portfolio With New Product Offerings

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q1 2020 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 0.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Matches Q1 Earnings Estimates

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

Hologic (HOLX) gains from several positive developments.

Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?

Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.

Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

Hologic (HOLX) Up 13.2% Since Last Earnings Report: Can It Continue?

A Relative Strength Rating upgrade for Hologic shows improving technical performance. Will it continue?

Stock Upgrades: Hologic Shows Rising Relative Strength

Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.

Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA

Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.

Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark

Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

Hologic (HOLX) Set to Divest Medical Aesthetics Business

Hologic Inc. HOLX, +0.81% said Wednesday it has agreed to sell its Cynosure medical aesthetics business to funds managed by private-equity firm Clayton, Dubilier & Rice for $205 million in cash.

Hologic to sell underperforming Cynosure business for proceeds of about $138 million

The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.

Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod

This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.

Hologic's Aptima Genitalium Assay Gets Clinically Verified

Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.

Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q4 2019 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 2.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q4 Earnings Match Estimates

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

Chairman, President and CEO of Hologic Inc (30-Year Financial, Insider Trades) Stephen P Macmillan (insider trades) sold 194,396 shares of HOLX on 08/05/2019 at an average price of $48.77 a share.

Hologic Inc (HOLX) Chairman, President and CEO Stephen P Macmillan Sold $9.5 million of Shares

Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.

Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q3 2019 Results - Earnings Call Transcript

News for Hologic Stock (HOLX)